The first and only approved treatment to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with Stage 2 T1D.1
If fewer than 2 AAbs are detected, additional screening may be appropriate for high-risk patients.2
If an OGTT is not available, an alternative method for diagnosing dysglycemia without overt hyperglycemia may be appropriate.1
Other methods that may be appropriate are available in the ADA and ISPAD guidelines.
Most common adverse reactions (>10%) were lymphopenia, rash, leukopenia, and headache.